Skip to main navigationSkip to main content
The University of Southampton
(023) 8120 3483

Dr Simon Crabb BSc, MBBS, MRCP, PhD

Associate Professor in Medical Oncology

Dr Simon Crabb's photo

Dr Simon Crabb is an Associate Professor in Medical Oncology within Medicine at the University of Southampton.

Dr Crabb graduated in medicine from St George’s Hospital Medical School, London in 1996. He joined the University of Southampton in 2002 as a Cancer Research UK Clinical Research Fellow and was awarded his PhD in 2006 for work involving novel histone deacetylase inhibitors. Following a Clinical Research Fellowship at the BC Cancer Agency in Vancouver, he returned to the Cancer Sciences Unit in Southampton where he now works as an Associate Professor and Honorary Consultant in Medical Oncology.

Dr Crabb’s research interests are in the development of novel therapeutic strategies for bladder cancer and prostate cancer, epigenetic therapeutic agents and mechanisms of systemic treatment resistance. He is an active clinical and translational researcher who leads and collaborates on a number of early phase clinical trials for genitourinary cancers.


BSc, Biochemistry, University of London, 1993

MBBS, Medicine, University of London, 1996

MRCP, Royal College of Physicians, 2000

PhD, University of Southampton, 2006

Appointments held

Associate Professor in Medical Oncology, University of Southampton Faculty of Medicine

Honorary Consultant in Medical Oncology, University Hospital Southampton NHS Foundation Trust

Research interests

Dr Crabb's research interests are focused on the development of new therapeutic options for genitourinary cancers, early phase clinical trials, epigenetic therapeutic agents and mechanisms of systemic treatment resistance. Current aspects of this include the following:

  • Investigating the impact on androgen receptor signalling of the histone demethylase lysine-specific histone demethylase 1A (LSD1, KDM1A) in prostate cancer
  • Testing the hypothesis that the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a mediator, in part, of cisplatin resistance in bladder cancer and potential means to reverse this therapeutically
  • Investigation of the role of V-ATPases in androgen receptor signalling in prostate cancer
  • Chief Investigator of the SPIRE trial, which is testing the use of the DNA methyltransferase inhibitor guadecitabine in combination with cisplatin based chemotherapy for bladder cancer
  • Chief Investigator of the ProCAID trial testing the addition of the AKT inhibitor AZD5363 to chemotherapy in prostate cancer

Research group

Cancer Sciences

Affiliate research group

Cancer Sciences Research group

Southampton Clinical Trials Unit, Associate Clinical Director from 2018

Southampton Experimental Cancer Medicine Centre, Deputy Director

Southampton Phase I Cancer Trials Clinic, lead from 2016

Advanced Bladder Cancer Subgroup of the NCRI Bladder Cancer Clinical Studies Group, member from 2010, Chair from 2014 to 2018

Bladder Cancer Genomics England Clinical Interpretation Partnership for the 100,000 Genomes Project, Chair

Cancer Sub-Specialty Lead, Urology Clinical Research, Wessex NIHR Clinical Research Network, from 2015

Cancer Research UK Experimental Medicine Expert Review Panel, member from 2015

ECMC Combination Alliance Extended Joint Steering Committee, member from 2015


Prior roles

NCRI Bladder and Renal Cancer Clinical Studies Group, member 2012 to 2018

NCRI Prostate Cancer Clinical Studies Group, member 2012 to 2018

British Association for Cancer Research Executive Committee, member 2012 to 2015


Sort via:TypeorYear


Book Chapter




BM5 and BM4. Provides clinical teaching to all years, based at Southampton General Hospital

Dr Simon Crabb
Somers Cancer Research Building Southampton General Hospital
Mailpoint 824 Tremona Road Southampton SO16 6YD

Room Number: SGH/CSB/MP824

Facsimile: (023) 8120 5152

Share this profile Share this on Facebook Share this on Twitter Share this on Weibo
Privacy Settings